![Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/11/e003743/F3.large.jpg)
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - ScienceDirect Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204518307009-gr4.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - ScienceDirect
![Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post](https://ascopost.com/media/14018767/117-wolchok.jpeg?anchor=center&mode=crop&width=400&height=300&rnd=132835446850000000)
Long-Term Outcomes From CheckMate 067 Nivolumab/Ipilimumab, Nivolumab, or Ipilimumab in Advanced Melanoma - The ASCO Post
![Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/11/e003743/F1.large.jpg)
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 | Journal for ImmunoTherapy of Cancer
![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom0cUEAAIXOn.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom06UEAAQejo.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_fig_thumbnail-1639066418803.png)
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/23dbeed54cde655fb6a12697b02c9ff303515da7/11-Table2-1.png)
PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/52c41546-392d-4834-a98c-2fe8fac43e2c/gr2_lrg.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
Baseline serum CRP levels are associated with overall survival (OS).... | Download Scientific Diagram
![Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0112-1/MediaObjects/41669_2018_112_Fig2_HTML.png)
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_fig-1639066418797.png)